7499-65-2

Usage

Nitro derivative of naphthalene

A nitro group (-NO2) and a bromo group (-Br) are attached to the naphthalene ring, which is a fused system of two benzene rings.

Building block in organic synthesis

1-bromo-3-nitronaphthalene is commonly used to create more complex molecules, as it can undergo various chemical reactions.

Potential mutagen

1-bromo-3-nitronaphthalene may cause mutations in genetic material, which can lead to harmful effects on human health.

Safety precautions

Proper handling and safety measures should be taken when working with 1-bromo-3-nitronaphthalene to minimize the risk of exposure and potential health hazards.

InChI:InChI=1/C10H6BrNO2/c11-10-6-8(12(13)14)5-7-3-1-2-4-9(7)10/h1-6H

Upstream product

• 90767-01-4 4-bromo-2-nitro-1-naphthylamine 
• 7664-93-9 sulfuric acid 
• 7726-95-6 bromine 
• 607-23-8 2-nitro-1-naphthylamine 
• 91394-66-0 1-(acetylamino)-4-bromonaphthalene 
• 7499-73-2 N-(4-bromo-2-nitronaphthalen-1-yl)acetamide 
• 2298-07-9 4-Bromo-1-naphthylamine 

Downstream Products

• 74924-94-0 4-bromonaphthalene-2-amine 
• 91-59-8 naphthalen-2-ylamine 
• 4507-84-0 3-nitro-1-naphthoic acid 
• 32018-86-3 3-aminonaphthalene-1-carboxylic acid 
• 52358-73-3 1,3-dibromonaphthalene 
• 1578179-15-3 2-(4-iodonaphthalen-2-ylamino)-5-nitrobenzoic acid 
• 147397-59-9 1-cyano-3-methoxynaphthalene 
• 147397-60-2 3-methoxy-1-naphthoic acid 
• 5498-31-7 4-bromo-naphthalen-2-ol 
• 51671-06-8 1-bromo-3-chloronaphthalene 

Relevant academic research and scientific papers

KRAS G12D INHIBITORS

The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

Monna, a potent and selective blocker for transmembrane protein with unknown function 16/anoctamin-1

Transmembrane protein with unknown function 16/anoctamin-1 (ANO1) is a protein widely expressed in mammalian tissues, and it has the properties of the classic calcium-activated chloride channel (CaCC). This protein has been implicated in numerous major physiological functions. However, the lack of effective and selective blockers has hindered a detailed study of the physiological functions of this channel. In this study, we have developed a potent and selective blocker for endogenous ANO1 in Xenopus laevis oocytes (xANO1) using a drug screening method we previously established (Oh et al., 2008). We have synthesized a number of anthranilic acid derivatives and have determined the correlation between biological activity and the nature and position of substituents in these derived compounds. A structure-activity relationship revealed novel chemical classes of xANO1 blockers. The derivatives contain a-NO2 group on position 5 of a naphthyl group-substituted anthranilic acid, and they fully blocked xANO1 chloride currents with an IC 5050 of 0.08 μM for xANO1. Selectivity tests revealed that other chloride channels such as bestrophin-1, chloride channel protein 2, and cystic fibrosis transmembrane conductance regulator were not appreciably blocked by 10～30 μM MONNA. The potent and selective blockers for ANO1 identified here should permit pharmacological dissection of ANO1/CaCC function and serve as potential candidates for drug therapy of related diseases such as hypertension, cystic fibrosis, bronchitis, asthma, and hyperalgesia.